This hexapeptide is equivalent to a sequence found on the A1 chain of laminin; it exhibits pro-angiogenic activity. Like other laminin peptides, this sequence can be used in combination with chemotherapeutics to deliver the drug to target tumor tissues. In vitro, this peptide increases vessel formation and migration. This peptide also increases secretion of matrix metalloproteinases 2 and 9 (MMP2/9), modulating the morphology of salivary gland adenoid cystic carcinoma cells.
| Purity | ≥98% |
|---|---|
| Formula | C82H148N31O26S |
| Formula Wt. | 2016.30 |
| Synonym | Laminin A Chain (2091-2108) |
| Appearance | White Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | L0250 Info Sheet PDF |
|---|
Stevenson M, Hale AB, Hale SJ, et al. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins. Cancer Gene Ther. 2007 Apr;14(4):335-45. PMID: 17235355.
Freitas VM, Scheremeta B, Hoffman MP, et al. Laminin-1 and SIKVAV a laminin-1-derived peptide, regulate the morphology and protease activity of a human salivary gland adenoid cystic carcinoma cell line. Oral Oncol. 2004 May;40(5):483-9. PMID: 15006619.
Kibbey MC, Corcoran ML, Wahl LM, et al. Laminin SIKVAV peptide-induced angiogenesis in vivo is potentiated by neutrophils. J Cell Physiol. 1994 Jul;160(1):185-93. PMID: 7517404.
